The company focuses on developing medicines for diseases based on insights into the biology and connectivity of the brain, immune, and gut systems. By identifying, shaping, and de-risking high-conviction assets and scaling them through dedicated structures backed by external capital, PureTech accelerates their path to patients while creating sustainable value for shareholders.
Cyborg Score Rationale
PureTech's founded entity Gallop Oncology announced positive Phase 1b results for LYT-200, with initial median overall survival of 13.2 months in AML combination therapy, exceeding expected late-line survival of <2.5 months. The company launched Celea Therapeutics to advance deupirfenidone (LYT-100), with Phase 3 trial initiation expected in the first half of 2026. Capital efficiency and de-risking strategy demonstrate execution capability.
Top Insights
Hub-and-spoke model reduces corporate overhead while preserving upside through Founded Entities—Celea and Gallop expected to transition operational costs off balance sheet in 2026
LYT-200 (Gallop Oncology) showing durable clinical responses in relapsed/refractory AML with favorable tolerability profile; FDA Fast Track and Orphan Drug designations granted
LYT-100 (Celea Therapeutics) positioned for Phase 3 IPF trial launch in H1 2026, addressing significant unmet need in pulmonary fibrosis
$319.6M cash runway extending into 2028; significant expense reduction anticipated as Founded Entities assume operational responsibility